Genflow Biosciences PLC Announces Result of GM

Rhea-AI Summary

Genflow Biosciences (LSE:GENF / OTCQB:GENFF) announced that all resolutions at its General Meeting on March 2, 2026 were duly passed by shareholders. Proxy voting showed strong support for both the directors' authority to allot securities and the disapplication of pre-emption rights.

The company reported vote totals and percentages for each resolution, with over 97% of votes cast in favour on both items and detailed proxy counts provided.

Results of General Meeting

LONDON, UK / ACCESS Newswire / March 2, 2026 / Genflow Biosciences Plc (LSE:GENF)(OTCQB:GENFF) ("Genflow" or "the Company") a leading European-based biotechnology company focusing on longevity, is pleased to announce that all resolutions proposed at the General Meeting held earlier today were duly passed by shareholders. The number of proxy votes for each resolution submitted prior to the meeting are presented below.

Proxy Voting Results

Ordinary Resolutions	Votes for	% of votes cast for	Votes Against	% of votes cast against	Votes withheld	Total votes cast
1. To approve the Director's authority to allot securities.	224,571,419	98.2%	3,787,114	1.7%	429,987	228,788,520
Special Resolution	Votes for	% of votes cast for	Votes Against	% of votes cast against	Votes withheld	Total votes cast
2. To disapply statutory pre-emption rights.	222,245,570	97.1%	5,141,463	2.2%	1,401,487	228,788,520

Contacts Genflow Biosciences	Harbor Access
Dr Eric Leire, CEO	Jonathan Paterson, Investor Relations
+32-477-495-881	+1 475 477 9401
	Jonathan.Paterson@Harbor-access.com

About Genflow

Founded in 2020, Genflow Biosciences Plc. (LSE:GENF) (OTCQB:GENFF), a biotechnology company headquartered in the UK with R&D facilities in Belgium, is pioneering gene therapies to decelerate the aging process, with the goal of promoting longer and healthier lives while mitigating the financial, emotional, and social impacts of a fast-growing aging global population. Genflow's lead compound, GF-1002, delivers a proprietary centenarian variant of the SIRT6 gene. The therapy is currently being evaluated in the Company's randomised, blinded SLAB (Sarcopenia and Longevity in Aged Beagles) study in dogs aged over 10 years, which commenced in March 2025. Preliminary interim results demonstrated improved survival versus control during the dosing period, alongside favourable safety and tolerability and positive trends across functional endpoints including muscle mass preservation, frailty reduction and quality of life. Other programs include a clinical trial that will explore the potential benefits of GF-1002 in treating MASH (Metabolic Dysfunction-Associated Steatohepatitis), the most prevalent chronic liver disease for which there is no effective treatments. Please visit www.genflowbio.com and follow the Company on LinkedIn and X.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

SOURCE: Genflow Biosciences PLC

View the original press release on ACCESS Newswire

FAQ

What resolutions did Genflow Biosciences (GENFF) pass at the March 2, 2026 General Meeting?

All resolutions were passed, including authority to allot securities and disapplication of pre-emption rights. According to the company, proxy voting showed 98.2% in favour of allotment authority and 97.1% in favour of disapplying pre-emption rights, with detailed vote counts published.

How much shareholder support did GENFF receive for the directors' authority to allot securities on March 2, 2026?

The directors' allotment authority received strong shareholder backing at 98.2% of votes cast in favour. According to the company, the proxy totals were 224,571,419 votes for, 3,787,114 votes against, and 429,987 votes withheld.

What were the proxy voting numbers for the GENFF resolution to disapply pre-emption rights?

The disapplication of pre-emption rights was approved with 222,245,570 votes for and 5,141,463 votes against. According to the company, total votes cast equalled 228,788,520 with 1,401,487 votes withheld.

Does the March 2, 2026 General Meeting result change Genflow Biosciences' share issuance powers (GENFF)?

Yes; the meeting approved the directors' authority to allot securities and to disapply pre-emption rights. According to the company, these approvals give the board the specified allotment and waiver powers as reflected in the passed resolutions.

Where can investors find the exact vote counts for GENFF's March 2, 2026 General Meeting?

Investors can view the detailed proxy vote counts published with the meeting results. According to the company, the announcement included tables showing vote totals, percentages for and against, and votes withheld for each resolution.